background: we aimed here to investigate the association between alleles and genotypes of apoe and age-related macular degeneration (amd) development. materials and methods: after ophthalmological examination, 120 patients with confirmed amd and 120 healthy controls were enrolled in the study. the polymorphic segment of apoe gene was pcr-amplified and sequenced to determine the frequency distri...

purpose : to offer a semi-automatic algorithm to determine the area of angiographic hyperfluorescence methods : the proposed algorithm included wavelet filter, histogram equalization and modified otsu thresholding. hyperfluorescent area of 30 angiographic images obtained from patients with leaking choroidal neovascularization (cnv) and diabetic retinopathy were evaluated and the results were co...

PURPOSE To assess the efficacy of triple combination therapy (TCT) including bevacizumab (BEV), low-fluence photodynamic therapy, and posterior sub-Tenon's triamcinolone acetonide in patients with wet age-related macular degeneration. METHODS This institutional review board-approved retrospective consecutive case series included 31 eyes treated for wet age-related macular degeneration with TC...

PURPOSE To measure visual acuity and metamorphopsia in patients with age-related macular degeneration (AMD) and to explore their relationship with macular lesions. METHODS In this cross-sectional study, a total of 32 normal subjects (32 eyes) and 35 AMD patients (35 eyes) were recruited. They were categorized into 4 groups: normal, dry AMD, non-active wet AMD, and active wet AMD. Best-correct...

PURPOSE To determine the influence of omega-3 supplementation on vitreous vascular endothelial growth factor A (VEGF-A) levels in patients with exudative age-related macular degeneration (wet AMD) receiving intravitreal anti-VEGF treatment. DESIGN Prospective, randomized, open-label, single-center, clinical trial, consecutive interventional case series. METHODS The study included 3 cohorts ...

Pegaptanib (Eyetech Pharmaceuticals and Pfizer), which was approved by the FDA at the end of 2004, was the first anti-VEGF therapy for neovascular AMD (3). After approval of bevacizumab (Genentech/ Roche) for cancer therapy and in view of the suspected role of VEGF in wet AMD, systemic intravenous and, later, intravitreal bevacizumab began to be administered off-label to treat neovascular AMD (...

PURPOSE To describe new, efficient predictors of maximum reading speed (MRS) in age-related macular degeneration (AMD) patients with central field loss. Type of AMD (wet versus dry) was scrutinized, because this factor seems to offer a promising model of differential visual adaptation induced by different temporal courses of disease progression. METHODS Linear mixed-effects (LME) analyses wer...

Age-related macular degeneration (AMD) is one of the leading causes blindness in elderly, affecting macula retina and resulting vision loss. There are two types AMD, wet dry, both which cause visual impairment. Wet AMD called neovascular (nAMD) characterized by formation choroidal vessels (CNVs) macula. nAMD can be treated with intravitreal injections vascular endothelial growth factor (VEGF) i...